Keros Therapeutics has managed to execute an IPO, hitting the top end of its pricing range and selling more … their CD20XCD30 bispecific now being tested in a range of blood cancers, in …
( read original story …)
The Taiwan NEWS
Keros Therapeutics has managed to execute an IPO, hitting the top end of its pricing range and selling more … their CD20XCD30 bispecific now being tested in a range of blood cancers, in …
( read original story …)